JP2018508229A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508229A5 JP2018508229A5 JP2017557264A JP2017557264A JP2018508229A5 JP 2018508229 A5 JP2018508229 A5 JP 2018508229A5 JP 2017557264 A JP2017557264 A JP 2017557264A JP 2017557264 A JP2017557264 A JP 2017557264A JP 2018508229 A5 JP2018508229 A5 JP 2018508229A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- seq
- amino acid
- acid sequence
- single domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 40
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 16
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims 2
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 claims 1
- 229930186217 Glycolipid Natural products 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2014192 | 2015-01-27 | ||
| NL2014192 | 2015-01-27 | ||
| PCT/NL2016/050064 WO2016122320A1 (en) | 2015-01-27 | 2016-01-27 | Single domain antibodies targeting cd1d |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020127379A Division JP7165701B2 (ja) | 2015-01-27 | 2020-07-28 | Ｃｄ１ｄを標的とする単一ドメイン抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508229A JP2018508229A (ja) | 2018-03-29 |
| JP2018508229A5 true JP2018508229A5 (https=) | 2019-03-07 |
| JP6743051B2 JP6743051B2 (ja) | 2020-08-19 |
Family
ID=52630466
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557264A Active JP6743051B2 (ja) | 2015-01-27 | 2016-01-27 | Ｃｄ１ｄを標的とする単一ドメイン抗体 |
| JP2020127379A Active JP7165701B2 (ja) | 2015-01-27 | 2020-07-28 | Ｃｄ１ｄを標的とする単一ドメイン抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020127379A Active JP7165701B2 (ja) | 2015-01-27 | 2020-07-28 | Ｃｄ１ｄを標的とする単一ドメイン抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US10501541B2 (https=) |
| EP (1) | EP3250608B1 (https=) |
| JP (2) | JP6743051B2 (https=) |
| KR (2) | KR20230132604A (https=) |
| CN (2) | CN107531787B (https=) |
| AU (2) | AU2016212777B2 (https=) |
| CA (1) | CA2975078A1 (https=) |
| EA (1) | EA201791691A1 (https=) |
| MX (1) | MX386714B (https=) |
| SG (1) | SG11201706128PA (https=) |
| WO (1) | WO2016122320A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107531787B (zh) | 2015-01-27 | 2022-01-18 | 拉法医疗有限公司 | 靶向cd1d的单域抗体 |
| WO2020060406A1 (en) | 2018-09-19 | 2020-03-26 | Lava Therapeutics B.V. | Novel bispecific antibodies for use in the treatment of hematological malignancies |
| CA3121478A1 (en) * | 2018-11-30 | 2020-06-04 | Aleta Biotherapeutics Inc. | Single domain antibodies against cll-1 |
| EP3792283A1 (en) | 2019-09-16 | 2021-03-17 | Lava Therapeutics B.V. | Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies |
| CN117222414A (zh) | 2021-03-01 | 2023-12-12 | 脱落性治疗公司 | 用于激活恒定自然杀伤t-细胞的化合物和用于消除炎性衰老细胞的方法 |
| JP2024538958A (ja) | 2021-10-21 | 2024-10-28 | ラヴァ・セラピューティクス・エヌ・ヴイ | ガンマデルタｔ細胞活性化抗体の使用 |
| CN114195891B (zh) * | 2021-12-22 | 2023-05-12 | 北京世纪沃德生物科技有限公司 | 一种crp驼源单域抗体及其制备方法和应用 |
| EP4285926A1 (en) * | 2022-05-30 | 2023-12-06 | LAVA Therapeutics N.V. | Combination treatment for chronic lymphocytic leukemia |
| EP4292610A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Variant antibodies that bind gamma-delta t cell receptors |
| WO2024256586A1 (en) | 2023-06-14 | 2024-12-19 | LAVA Therapeutics N.V. | Cd1d antibodies and methods of use |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2698880B1 (fr) | 1992-11-25 | 1995-02-24 | Inst Nat Sante Rech Med | Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques. |
| ES2201078T3 (es) | 1993-06-21 | 2004-03-16 | Brigham And Women's Hospital | Metodos de aislar antigenos presentados por cd1, vacunas que comprenden antigenos presentados por cd1, y lineas celulares para usar en dichos metodos. |
| CA2361678A1 (en) | 1999-02-05 | 2000-08-10 | Rijksuniversiteit Leiden | Method of modulating metabolite biosynthesis in recombinant cells |
| EP1198572A2 (en) | 1999-08-02 | 2002-04-24 | Keygene N.V. | Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants |
| WO2001022816A1 (en) | 1999-09-30 | 2001-04-05 | National Jewish Medical And Research Center | MODULATION OF ηδ T CELLS TO REGULATE AIRWAY HYPERRESPONSIVENESS |
| US6737398B1 (en) | 1999-09-30 | 2004-05-18 | National Jewish Medical And Research Center | Modulation of γδ T cells to regulate airway hyperresponsiveness |
| AU2001259230A1 (en) | 2000-04-28 | 2001-11-12 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of polyclonal b cell activation and immunoglobulin class switching topathogenic autoantibodies by blocking cd1-mediated interactions |
| DK2336187T3 (en) | 2000-06-19 | 2016-08-22 | Beth Israel Deaconess Medical Ct Inc | Compositions and Methods of monoclonal and polyclonal antibodies which are specific for T-cell subpopulations |
| EP1372668B1 (en) | 2001-03-26 | 2011-12-07 | Dana-Farber Cancer Institute, Inc. | Method of attenuating reactions to skin irritants |
| US8178098B2 (en) | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
| KR101033196B1 (ko) | 2002-02-14 | 2011-05-09 | 이뮤노메딕스, 인코오포레이티드 | 항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법 |
| EP1532175B1 (en) | 2002-03-22 | 2012-10-17 | Aprogen, Inc. | Humanized antibody and process for preparing the same |
| AU2003234443A1 (en) * | 2002-05-01 | 2003-11-17 | Beth Israel Deaconess Medical Center | Use of anti-cd1 antibodies for the modulation of immune responses |
| US7521543B2 (en) | 2002-10-23 | 2009-04-21 | Ludwig Institute For Cancer Research | A34 and A33-like 3 DNA, proteins, antibodies thereto and methods of treatment using same |
| EP1587838B1 (en) | 2003-01-10 | 2015-04-15 | Ablynx N.V. | Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation |
| WO2005046711A2 (en) | 2003-11-07 | 2005-05-26 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Stimulation or inhibition of gamma delta t-cells to promote or inhibit bone healing |
| JP5139800B2 (ja) | 2004-06-03 | 2013-02-06 | ノビミューン エスアー | 抗ｃｄ３抗体およびその使用方法 |
| EP1778836B1 (en) | 2004-08-19 | 2010-08-04 | University College Cardiff Consultants Limited | Preparation of antigen-presenting human gamma delta t cells and use in immunotherapy |
| CA2584971C (en) | 2004-11-02 | 2013-08-06 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for inhibition of nkt cells |
| US8338173B2 (en) | 2005-08-11 | 2012-12-25 | University College Cardiff Consultants Limited | Preparation of antigen-presenting human γδ T cells and use in immunotherapy |
| EP1990410B1 (en) * | 2006-02-22 | 2020-01-08 | Riken | IMMUNOTHERAPY BY USING CELL CAPABLE OF CO-EXPRESSING TARGET ANTIGEN AND CD1d AND PULSED WITH CD1d LIGAND |
| GB0605247D0 (en) * | 2006-03-15 | 2006-04-26 | Chiron Srl | Compositions and methods for immunisation |
| EP1878440A1 (en) | 2006-07-13 | 2008-01-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds |
| US8012484B2 (en) | 2007-04-12 | 2011-09-06 | University Of Virginia Patent Foundation | Method of treating ischemia reperfusion injury by inhibiting NKT cell activity |
| EP2058388A1 (en) * | 2007-10-05 | 2009-05-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Non-conventional NKT cells for use in cancer therapy |
| WO2010130830A2 (en) * | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders |
| WO2013053021A1 (en) * | 2011-10-14 | 2013-04-18 | Cephalon Australia Pty Ltd | ANTIBODIES TO CD1d |
| AU2013201422B2 (en) | 2012-01-23 | 2015-04-09 | Ablynx Nv | Sequences directed against hepatocyte growth factor (HFG) and polypeptides comprising the same for the treatment of cancers and/or tumors |
| EP2831109B1 (en) | 2012-03-28 | 2017-12-06 | Gadeta B.V. | Combinatorial gamma 9 delta 2 t cell receptor chain exchange |
| WO2013174403A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014210522A1 (en) | 2013-06-28 | 2014-12-31 | The Scripps Research Institute | Nkt cell ligands and methods of use |
| DK3105252T3 (da) | 2014-02-12 | 2019-10-14 | Michael Uhlin | Bispecifikke antistoffer til anvendelse ved stamcelletransplantation |
| EP3129404B1 (en) | 2014-04-10 | 2026-01-28 | LAVA Therapeutics N.V. | Immunoglobulins binding human vgamma9vdelta2 t cell receptors |
| EP3144388B1 (en) | 2014-05-13 | 2020-07-01 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirecting antigen-binding molecule for cells having immunosuppression function |
| KR20170021354A (ko) | 2014-07-02 | 2017-02-27 | 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) | CD1d 제한된 감마/델타 T 세포 림프종을 진단 및 치료하는 방법 |
| WO2016081518A2 (en) | 2014-11-17 | 2016-05-26 | Adicet Bio, Inc. | Engineered gamma delta t-cells |
| CN107531787B (zh) | 2015-01-27 | 2022-01-18 | 拉法医疗有限公司 | 靶向cd1d的单域抗体 |
| US11000603B2 (en) | 2015-04-14 | 2021-05-11 | Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. | Multi-specific binding conjugate, related pharmaceutical compositions and use |
| CN104829730A (zh) | 2015-04-14 | 2015-08-12 | 苏静 | 一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用 |
| US11660340B2 (en) | 2015-11-18 | 2023-05-30 | Chugai Seiyaku Kabushiki Kaisha | Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function |
| CN109195992A (zh) | 2016-04-29 | 2019-01-11 | 本康生物制药（深圳）有限公司 | 多特异性结合偶联物、相关的药物组合物及应用 |
| CA3032304A1 (en) | 2016-07-29 | 2018-02-01 | New York University | Gamma delta t cells as a target for treatment of solid tumors |
| WO2018140831A2 (en) | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| WO2018229163A1 (en) | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
| TWI687227B (zh) | 2017-10-03 | 2020-03-11 | 生倍科技股份有限公司 | 用於t細胞免疫療法之組合及其用途 |
| RU2020135920A (ru) | 2018-04-05 | 2022-05-05 | Новартис Аг | Триспецифические связывающие молекулы против форм рака и пути их применения |
| EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| AU2020226904B2 (en) | 2019-02-21 | 2025-05-01 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| EP3965818A4 (en) | 2019-05-08 | 2023-05-31 | Janssen Biotech, Inc. | MATERIALS AND METHODS FOR MODULATION OF T-CELL-MEDIATED IMMUNITY |
| US20220290101A1 (en) | 2019-08-16 | 2022-09-15 | GammaDelta Therapeutics Limited | Ex vivo gamma delta t cell populations |
| CA3145523A1 (en) | 2019-08-16 | 2021-02-25 | GammaDelta Therapeutics Limited | Therapeutic uses of anti-tcr delta variable 1 antibodies |
| KR20220147631A (ko) | 2020-02-27 | 2022-11-03 | 얀센 바이오테크 인코포레이티드 | 면역 반응을 조절하기 위한 물질 및 방법 |
| IL296358A (en) | 2020-03-13 | 2022-11-01 | Janssen Biotech Inc | Materials and methods for modulating delta chain mediated immunity |
| AR123935A1 (es) | 2020-10-28 | 2023-01-25 | Janssen Biotech Inc | COMPOSICIONES Y MÉTODOS PARA MODULAR LA INMUNIDAD MEDIADA POR LA CADENA d g |
-
2016
- 2016-01-27 CN CN201680007612.0A patent/CN107531787B/zh not_active Withdrawn - After Issue
- 2016-01-27 CA CA2975078A patent/CA2975078A1/en active Pending
- 2016-01-27 SG SG11201706128PA patent/SG11201706128PA/en unknown
- 2016-01-27 AU AU2016212777A patent/AU2016212777B2/en not_active Revoked
- 2016-01-27 KR KR1020237029643A patent/KR20230132604A/ko active Pending
- 2016-01-27 KR KR1020177024072A patent/KR102574729B1/ko active Active
- 2016-01-27 US US15/546,406 patent/US10501541B2/en active Active
- 2016-01-27 CN CN202111671891.XA patent/CN114504645A/zh active Pending
- 2016-01-27 WO PCT/NL2016/050064 patent/WO2016122320A1/en not_active Ceased
- 2016-01-27 EP EP16715360.0A patent/EP3250608B1/en not_active Revoked
- 2016-01-27 EA EA201791691A patent/EA201791691A1/ru unknown
- 2016-01-27 JP JP2017557264A patent/JP6743051B2/ja active Active
- 2016-01-27 MX MX2017009680A patent/MX386714B/es unknown
-
2019
- 2019-10-29 US US16/666,734 patent/US11591394B2/en active Active
-
2020
- 2020-07-28 JP JP2020127379A patent/JP7165701B2/ja active Active
-
2022
- 2022-02-11 AU AU2022200922A patent/AU2022200922A1/en not_active Withdrawn
-
2023
- 2023-01-30 US US18/161,163 patent/US12110328B2/en active Active
-
2024
- 2024-09-03 US US18/822,745 patent/US20240425592A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018508229A5 (https=) | ||
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| RU2016129517A (ru) | Биспецифические антитела к her2 и способы применения | |
| CO2018013500A2 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
| BR112019012040A2 (pt) | anticorpo isolado ou fragmento do mesmo, composição, célula isolada, e, métodos para tratamento de câncer, para detecção da expressão de cd73 em uma amostra e para identificação de um paciente com câncer adequado para o tratamento com uma terapia anti-cd73. | |
| WO2012149365A3 (en) | Antibodies selective for pathological tau dimers and oligomers and their uses in treatment, diagnosis, monitoring of tauopathies | |
| CO2018005932A2 (es) | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas | |
| JP2013502204A5 (https=) | ||
| JP2013538796A5 (https=) | ||
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| CY1121249T1 (el) | Αντισωμα εναντι του ειδικου προστατικου αντιγονου βλαστικου κυτταρου και χρησεις αυτου | |
| JP2018527919A5 (https=) | ||
| HK1257730A1 (zh) | 抗despr单克隆抗体用於癌症和中风的靶向疗法及成像 | |
| UA105009C2 (uk) | Композиції та способи, призначені для спрямованого впливу антитіл на білок с5 системи комплементу | |
| BR112017019785A2 (pt) | anticorpos terapêuticos e seus usos | |
| EA201591131A1 (ru) | Днк-конструкции антитела и способ их применения | |
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| PH12020550598A1 (en) | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells | |
| RU2017107773A (ru) | Антитела, специфичные к ммр9 | |
| CY1115349T1 (el) | Εξανθρωπισμενα αντι cxcr4 αντισωματα για τη θεραπεια καρκινου | |
| Naidoo et al. | Nanobodies enhancing cancer visualization, diagnosis and therapeutics | |
| RU2016143552A (ru) | Гуманизированные антитела к антигену Томсена-Фриденрайха | |
| RU2017111584A (ru) | Антитело против злокачественной клетки, противораковое лекарственное средство и способ тестирования злокачественного новообразования | |
| BR112017027702A2 (pt) | anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2) | |
| EA202191658A1 (ru) | Антитела против фактора c2b комплемента человека и способы применения |